BACKGROUND: Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine. Some clinicians think that HFS is a type of inflammation limited to the hands and feet and can be prevented with a COX-2 inhibitor (celecoxib). METHODS: We designed a single-center, prospective randomized clinical trial to test the hypothesis. From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily. All patients were divided randomly into two groups treated with or without celecoxib. All adverse events were recorded. RESULTS: Grade 1 and grade 2 HFS were more common in the capecitabine group than in the capecitabine/celecoxib group (74.6% versus 57.4%, P = 0.034, 29.6% versus 14.7% P = 0.035). The use of celecoxib (P < 0.001, P = 0.003) and the level of dihydropyrimidine dehydrogenase (P = 0.048, P = 0.014) affected the incidence of grade 1 and 2 HFS, as determined by log-rank analysis. Multivariate Cox proportional hazards regression analysis indicated that the use of celecoxib was the only factor that affected the incidence of ≥ grade 1 HFS [Hazard Ratio (HR): 0.556, P = 0.001] and ≥ grade 2 HFS (HR: 0.414, P = 0.005). CONCLUSIONS:Celecoxib can be used effectively and safely to prevent capecitabine-related HFS.
RCT Entities:
BACKGROUND:Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine. Some clinicians think that HFS is a type of inflammation limited to the hands and feet and can be prevented with a COX-2 inhibitor (celecoxib). METHODS: We designed a single-center, prospective randomized clinical trial to test the hypothesis. From August 2008 to December 2010, stage II and III colorectal cancerpatients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily. All patients were divided randomly into two groups treated with or without celecoxib. All adverse events were recorded. RESULTS: Grade 1 and grade 2 HFS were more common in the capecitabine group than in the capecitabine/celecoxib group (74.6% versus 57.4%, P = 0.034, 29.6% versus 14.7% P = 0.035). The use of celecoxib (P < 0.001, P = 0.003) and the level of dihydropyrimidine dehydrogenase (P = 0.048, P = 0.014) affected the incidence of grade 1 and 2 HFS, as determined by log-rank analysis. Multivariate Cox proportional hazards regression analysis indicated that the use of celecoxib was the only factor that affected the incidence of ≥ grade 1 HFS [Hazard Ratio (HR): 0.556, P = 0.001] and ≥ grade 2 HFS (HR: 0.414, P = 0.005). CONCLUSIONS:Celecoxib can be used effectively and safely to prevent capecitabine-related HFS.
Authors: Kathryn A Guerriero; Steven R Wilson; Nabil E Boutagy; Chi Liu; Albert J Sinusas; Caroline J Zeiss Journal: Comp Med Date: 2018-02-01 Impact factor: 0.982
Authors: S Jung; J Sehouli; R Chekerov; F Kluschke; A Patzelt; H Fuss; F Knorr; J Lademann Journal: Support Care Cancer Date: 2017-06-26 Impact factor: 3.603
Authors: Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse Journal: Support Care Cancer Date: 2014-01-26 Impact factor: 3.603
Authors: P G Corrie; R Bulusu; C B Wilson; G Armstrong; S Bond; R Hardy; S Lao-Sirieix; D Parashar; A Ahmad; F Daniel; M Hill; G Wilson; C Blesing; A M Moody; K McAdam; M Osborne Journal: Br J Cancer Date: 2012-07-19 Impact factor: 7.640
Authors: R-D Hofheinz; V Heinemann; L F von Weikersthal; R P Laubender; D Gencer; I Burkholder; A Hochhaus; S Stintzing Journal: Br J Cancer Date: 2012-10-02 Impact factor: 7.640